APOB and metabolic dysfunction-associated steatohepatitis: LDL-apoB FRRs were not different between healthy subjects, noncirrhotic, and cirrhotic NASH patients (supplemental Fig. S2A), which excludes a difference in LDL-apoB clearance efficiency (half-life), but LDL-apoB ASRs, calculated from plasma apoB100 concentrations multiplied by the FRR of LDL-apoB in each subject (26, 30), were significantly lower in cirrhotic versus noncirrhotic NASH subjects (P = 0.03, supplemental Fig. S2B).